Researchers used a tranche of data from patients who had been prescribed a GLP-1 for diabetes or obesity between 2021-2022
Oral administration is the least predictable
Exosomes or PRP carry more evidence for that indication
According to the Pan American Health Organization (PAHO), over 62 million people in the Americas live with diabetes, while awareness campaigns have expanded screening and treatment access across more than 35 countries, supporting increased adoption of advanced therapies including GLP-1 drugs
For example, in the context of clear cell renal cell carcinoma development, loss of SDH genes has been shown to dampen oxidative phosphorylation and reduce susceptibility to ferroptosis 112
Doctors Data GI360 provides individualized profiling of the gut microbiome including diversity, dysbiosis, keystone bacteria and SCFAs